Last reviewed · How we verify
Seroquel and Risperidone
Both drugs are atypical antipsychotics that block dopamine D2 receptors and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.
Both drugs are atypical antipsychotics that block dopamine D2 receptors and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Irritability associated with autism spectrum disorder (risperidone).
At a glance
| Generic name | Seroquel and Risperidone |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Seroquel (quetiapine) and Risperidone are second-generation antipsychotics that antagonize dopamine D2 and serotonin 5-HT2A receptors, with additional activity at other serotonergic and adrenergic receptors. By blocking these neurotransmitter pathways, they reduce positive symptoms (hallucinations, delusions) and negative symptoms of psychosis, and are also used for mood stabilization in bipolar disorder. Risperidone has higher D2 receptor affinity and potency compared to quetiapine.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute mania and maintenance)
- Irritability associated with autism spectrum disorder (risperidone)
- Major depressive disorder (adjunctive, quetiapine)
Common side effects
- Weight gain
- Sedation/somnolence
- Extrapyramidal symptoms (tremor, rigidity, akathisia)
- Prolactin elevation/hyperprolactinemia
- Orthostatic hypotension
- Metabolic syndrome/dyslipidemia
- Akathisia
Key clinical trials
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Magnetic Seizure Therapy for Psychotic Disorders (NA)
- National Pregnancy Registry for Psychiatric Medications
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- Deprescribing Antipsychotics in Long-Term Care (NA)
- A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication (PHASE2)
- A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Seroquel and Risperidone CI brief — competitive landscape report
- Seroquel and Risperidone updates RSS · CI watch RSS
- AstraZeneca portfolio CI